

# Lin Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/861331/publications.pdf>

Version: 2024-02-01

231  
papers

14,169  
citations

18436

62  
h-index

22102

113  
g-index

240  
all docs

240  
docs citations

240  
times ranked

9307  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Bowel Disorders. <i>Gastroenterology</i> , 2016, 150, 1393-1407.e5.   | 0.6  | 1,912     |
| 2  | Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. <i>Gastroenterology</i> , 2016, 150, 1481-1491.  | 0.6  | 400       |
| 3  | V. Stress and irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2001, 280, G519-G524.  | 1.6  | 362       |
| 4  | Gender, Age, Society, Culture, and the Patient's Perspective in the Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1435-1446.                                    | 0.6  | 320       |
| 5  | Cerebral Activation in Patients With Irritable Bowel Syndrome and Control Subjects During Rectosigmoid Stimulation. <i>Psychosomatic Medicine</i> , 2001, 63, 365-375.                        | 1.3  | 291       |
| 6  | Review article: epidemiology and quality of life in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 31-39.                                 | 1.9  | 288       |
| 7  | Gender differences in irritable bowel syndrome. <i>Gastroenterology</i> , 2002, 123, 1686-1701.   | 0.6  | 268       |
| 8  | Sex-related differences in IBS patients: central processing of visceral stimuli. <i>Gastroenterology</i> , 2003, 124, 1738-1747.  | 0.6  | 264       |
| 9  | Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. <i>Pain</i> , 2005, 115, 398-409.                                      | 2.0  | 251       |
| 10 | Association Between Early Adverse Life Events and Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 385-390.e3.   | 2.4  | 251       |
| 11 | A Comparison of Visceral and Somatic Pain Processing in the Human Brainstem Using Functional Magnetic Resonance Imaging. <i>Journal of Neuroscience</i> , 2005, 25, 7333-7341.                | 1.7  | 234       |
| 12 | Chronic constipation. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17095.   | 18.1 | 203       |
| 13 | The Central Role of Gastrointestinal-Specific Anxiety in Irritable Bowel Syndrome: Further Validation of the Visceral Sensitivity Index. <i>Psychosomatic Medicine</i> , 2007, 69, 89-98.     | 1.3  | 196       |
| 14 | The Role of Stress on Physiologic Responses and Clinical Symptoms in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 140, 761-765.e5.   | 0.6  | 194       |
| 15 | Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress. <i>American Journal of Gastroenterology</i> , 2003, 98, 135-143.                        | 0.2  | 192       |
| 16 | Gender-related differences in IBS symptoms. <i>American Journal of Gastroenterology</i> , 2001, 96, 2184-2193.  | 0.2  | 190       |
| 17 | Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales. <i>American Journal of Gastroenterology</i> , 2014, 109, 1804-1814. | 0.2  | 190       |
| 18 | Longitudinal Change in Perceptual and Brain Activation Response to Visceral Stimuli in Irritable Bowel Syndrome Patients. <i>Gastroenterology</i> , 2006, 131, 352-365.                       | 0.6  | 175       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. <i>Pain</i> , 2000, 84, 297-307.   | 2.0 | 174       |
| 20 | Childhood Trauma Is Associated With Hypothalamic-Pituitary-Adrenal Axis Responsiveness in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2009, 137, 1954-1962.  | 0.6 | 167       |
| 21 | Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2001, 96, 3341-3347.   | 0.2 | 163       |
| 22 | Clinical Determinants of Health-Related Quality of Life in Patients With Irritable Bowel Syndrome. <i>Archives of Internal Medicine</i> , 2004, 164, 1773.   | 4.3 | 158       |
| 23 | Gender differences in regional brain response to visceral pressure in IBS patients. <i>European Journal of Pain</i> , 2000, 4, 157-172.  | 1.4 | 157       |
| 24 | A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2011, 106, 1803-1812.  | 0.2 | 156       |
| 25 | Is Irritable Bowel Syndrome a Diagnosis of Exclusion? A Survey of Primary Care Providers, Gastroenterologists, and IBS Experts. <i>American Journal of Gastroenterology</i> , 2010, 105, 848-858.  | 0.2 | 153       |
| 26 | Incidence of Ischemic Colitis and Serious Complications of Constipation Among Patients Using Alosetron: Systematic Review of Clinical Trials and Post-Marketing Surveillance Data. <i>American Journal of Gastroenterology</i> , 2006, 101, 1069-1079. | 0.2 | 151       |
| 27 | A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. <i>Gut</i> , 2005, 54, 1707-1713.  | 6.1 | 150       |
| 28 | Functional GI disorders: from animal models to drug development. <i>Gut</i> , 2008, 57, 384-404.   | 6.1 | 140       |
| 29 | Prevalence of irritable bowel syndrome among university students. <i>Journal of Psychosomatic Research</i> , 2003, 55, 501-505.  | 1.2 | 137       |
| 30 | Serum and Colonic Mucosal Immune Markers in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2012, 107, 262-272.  | 0.2 | 131       |
| 31 | Condition-specific deactivation of brain regions by 5-HT <sub>3</sub> receptor antagonist Alosetron. <i>Gastroenterology</i> , 2002, 123, 969-977.   | 0.6 | 128       |
| 32 | The Effect of Life Stress on Symptoms of Heartburn. <i>Psychosomatic Medicine</i> , 2004, 66, 426-434.   | 1.3 | 127       |
| 33 | Sex specific alterations in autonomic function among patients with irritable bowel syndrome. <i>Gut</i> , 2005, 54, 1396-1401.   | 6.1 | 127       |
| 34 | A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. <i>American Journal of Gastroenterology</i> , 2005, 100, 115-123.   | 0.2 | 125       |
| 35 | Preoperative Versus Postoperative Endoscopic Retrograde Cholangiopancreatography in Mild to Moderate Gallstone Pancreatitis. <i>Annals of Surgery</i> , 2000, 231, 82.   | 2.1 | 121       |
| 36 | Cortical processing of visceral and somatic stimulation: Differentiating pain intensity from unpleasantness. <i>Neuroscience</i> , 2005, 133, 533-542.   | 1.1 | 120       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. <i>Gut</i> , 2018, 67, 263-270.   | 6.1 | 120       |
| 38 | Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?. <i>Gender Medicine</i> , 2009, 6, 152-167.  | 1.4 | 116       |
| 39 | Characterization of the Alternating Bowel Habit Subtype in Patients with Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2005, 100, 896-904.  | 0.2 | 113       |
| 40 | American Gastroenterological Association Institute Technical Review on the Pharmacological Management of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 147, 1149-1172.e2.   | 0.6 | 113       |
| 41 | Predictors of Patient-Assessed Illness Severity in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, 2536-2543.  | 0.2 | 112       |
| 42 | MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. <i>Gastroenterology</i> , 2015, 149, 981-992.e11.  | 0.6 | 112       |
| 43 | Symptom Differences in Moderate to Severe Ibs Patients Based on Predominant Bowel Habit. <i>American Journal of Gastroenterology</i> , 1999, 94, 2929-2935.   | 0.2 | 109       |
| 44 | Brain Responses To Visceral and Somatic Stimuli in Patients With Irritable Bowel Syndrome With and Without Fibromyalgia. <i>American Journal of Gastroenterology</i> , 2003, 98, 1354-1361.   | 0.2 | 106       |
| 45 | A Focus Group Assessment of Patient Perspectives on Irritable Bowel Syndrome and Illness Severity. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1532-1541.  | 1.1 | 102       |
| 46 | Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 291, R277-R284.  | 0.9 | 97        |
| 47 | Diagnosis and management of IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 565-581.  | 8.2 | 96        |
| 48 | Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.   | 9.4 | 96        |
| 49 | Sex-based differences in gastrointestinal pain. <i>European Journal of Pain</i> , 2004, 8, 451-463.   | 1.4 | 93        |
| 50 | Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?. <i>American Journal of Gastroenterology</i> , 2008, 103, 2972-2976.  | 0.2 | 91        |
| 51 | Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1161-1168. | 1.9 | 90        |
| 52 | Gallstone Pancreatitis: A Prospective Study on the Incidence of Cholangitis and Clinical Predictors of Retained Common Bile Duct Stones. <i>American Journal of Gastroenterology</i> , 1998, 93, 527-531.   | 0.2 | 89        |
| 53 | Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1252-1260.  | 1.6 | 88        |
| 54 | Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. <i>American Journal of Gastroenterology</i> , 2002, 97, 2803-2811.   | 0.2 | 86        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Impact of Sex and Gender on Irritable Bowel Syndrome. <i>Biological Research for Nursing</i> , 2003, 5, 56-65.  | 1.0 | 85        |
| 56 | Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences. <i>American Journal of Gastroenterology</i> , 2010, 105, 866-875. | 0.2 | 77        |
| 57 | Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000134.  | 1.1 | 77        |
| 58 | Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome?. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 892-899.   | 0.5 | 74        |
| 59 | Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 152-156.  | 0.2 | 71        |
| 60 | Gastrointestinal and Psychological Mediators of Health-Related Quality of Life in IBS and IBD: A Structural Equation Modeling Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 451-459.                                   | 0.2 | 71        |
| 61 | Basic Pathophysiologic Mechanisms in Irritable Bowel Syndrome. <i>Digestive Diseases</i> , 2001, 19, 212-218.   | 0.8 | 69        |
| 62 | Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles. <i>Gastroenterology</i> , 2008, 135, 1877-1891.   | 0.6 | 65        |
| 63 | Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1673-1676.  | 2.4 | 64        |
| 64 | Attentional modulation of visceral and somatic pain. <i>Neurogastroenterology and Motility</i> , 2007, 19, 569-577.   | 1.6 | 63        |
| 65 | Developing Valid and Reliable Health Utilities in Irritable Bowel Syndrome: Results From the IBS PROOF Cohort. <i>American Journal of Gastroenterology</i> , 2009, 104, 1984-1991.  | 0.2 | 60        |
| 66 | Activation of pruritogenic TGR5, MrgprA3, and MrgprC11 on colon-innervating afferents induces visceral hypersensitivity. <i>JCI Insight</i> , 2019, 4, .  | 2.3 | 59        |
| 67 | Brain Responses to Visceral and Somatic Stimuli in Irritable Bowel Syndrome: a Central Nervous System Disorder?. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 271-279.  | 1.0 | 58        |
| 68 | A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: A Rome Foundation Working Team Report. <i>Gastroenterology</i> , 2021, 161, 1670-1688.e7.                                       | 0.6 | 56        |
| 69 | Functional Bowel Disorders: A Roadmap to Guide the Next Generation of Research. <i>Gastroenterology</i> , 2018, 154, 723-735.   | 0.6 | 55        |
| 70 | Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2018, 155, 168-179.   | 0.6 | 55        |
| 71 | Enhanced preattentive central nervous system reactivity in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2002, 97, 2791-2797.   | 0.2 | 54        |
| 72 | Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 411-420. | 0.8 | 52        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Expression of the Bitter Taste Receptor, T2R38, in Enteroendocrine Cells of the Colonic Mucosa of Overweight/Obese vs. Lean Subjects. <i>PLoS ONE</i> , 2016, 11, e0147468.  | 1.1 | 52        |
| 74 | Irritable Bowel Syndrome: Current Approach to Symptoms, Evaluation, and Treatment. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 665-685.   | 1.0 | 48        |
| 75 | A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 344-357.  | 1.4 | 47        |
| 76 | Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1114-1122.              | 1.9 | 47        |
| 77 | Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2017, 112, 892-899. | 0.2 | 47        |
| 78 | GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2488-2496.   | 1.1 | 45        |
| 79 | AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. <i>Gastroenterology</i> , 2022, 163, 118-136.   | 0.6 | 45        |
| 80 | New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments. <i>Current Gastroenterology Reports</i> , 2005, 7, 272-279.   | 1.1 | 44        |
| 81 | The effect of sex and irritable bowel syndrome on HPA axis response and peripheral glucocorticoid receptor expression. <i>Psychoneuroendocrinology</i> , 2016, 69, 67-76.  | 1.3 | 43        |
| 82 | Early adverse life events are associated with altered brain network architecture in a sex- dependent manner. <i>Neurobiology of Stress</i> , 2017, 7, 16-26.   | 1.9 | 43        |
| 83 | AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2022, 163, 137-151.   | 0.6 | 43        |
| 84 | The Association of Functional Gastrointestinal Disorders and Fibromyalgia. <i>The European Journal of Surgery</i> , 1998, 164, 32-36.  | 1.0 | 41        |
| 85 | Computer-Generated Vs. Physician-Documented History of Present Illness (HPI): Results of a Blinded Comparison. <i>American Journal of Gastroenterology</i> , 2015, 110, 170-179.   | 0.2 | 41        |
| 86 | Irritable bowel syndrome patients have <i>SCN5A</i> channelopathies that lead to decreased $Na^{+}$ current and mechanosensitivity. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G494-G503.         | 1.6 | 40        |
| 87 | Racial Differences in the Impact of Irritable Bowel Syndrome on Health-Related Quality of Life. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 782-789.   | 1.1 | 39        |
| 88 | Increased Acoustic Startle Responses in IBS Patients During Abdominal and Nonabdominal Threat. <i>Psychosomatic Medicine</i> , 2008, 70, 920-927.  | 1.3 | 39        |
| 89 | Resilience is decreased in irritable bowel syndrome and associated with symptoms and cortisol response. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13155.  | 1.6 | 39        |
| 90 | Morphological brain measures of corticostriatal inhibition related to resilience. <i>Journal of Neuroscience Research</i> , 2017, 95, 1760-1775.   | 1.3 | 38        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Review. <i>Gastroenterology</i> , 2022, 162, 1737-1745.e5.  | 0.6 | 38        |
| 92  | Autonomic response to a visceral stressor is dysregulated in irritable bowel syndrome and correlates with duration of disease. <i>Neurogastroenterology and Motility</i> , 2013, 25, e650-9.   | 1.6 | 37        |
| 93  | Differences in Gastrointestinal Symptoms According to Gender in Rome II Positive IBS and Dyspepsia in a Latin American Population. <i>American Journal of Gastroenterology</i> , 2010, 105, 925-932.   | 0.2 | 36        |
| 94  | Diminished Expression of Corticotropin-Releasing Hormone Receptor 2 in Human Colon Cancer Promotes Tumor Growth and Epithelial-to-Mesenchymal Transition via Persistent Interleukin-6/Stat3 Signaling. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 610-630. | 2.3 | 36        |
| 95  | Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1186-1192.   | 1.1 | 36        |
| 96  | Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 253-275.   | 1.4 | 36        |
| 97  | Understanding Gastrointestinal Distress: A Framework for Clinical Practice. <i>American Journal of Gastroenterology</i> , 2011, 106, 380-385.  | 0.2 | 34        |
| 98  | miR-24 Is Elevated in Ulcerative Colitis Patients and Regulates Intestinal Epithelial Barrier Function. <i>American Journal of Pathology</i> , 2019, 189, 1763-1774.   | 1.9 | 31        |
| 99  | Diagnosis and treatment of irritable bowel syndrome: State of the art. <i>Current Gastroenterology Reports</i> , 2005, 7, 249-256.   | 1.1 | 30        |
| 100 | Diagnostic approach to the patient with irritable bowel syndrome. <i>American Journal of Medicine</i> , 1999, 107, 20-26.  | 0.6 | 29        |
| 101 | Characteristics of Acute Pain Attacks in Patients With Irritable Bowel Syndrome Meeting Rome III Criteria. <i>American Journal of Gastroenterology</i> , 2011, 106, 1299-1307.   | 0.2 | 29        |
| 102 | Identification of a Functional TPH1 Polymorphism Associated With Irritable Bowel Syndrome Bowel Habit Subtypes. <i>American Journal of Gastroenterology</i> , 2013, 108, 1766-1774.  | 0.2 | 29        |
| 103 | Genome-wide DNA methylation profiling of peripheral blood mononuclear cells in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2016, 28, 410-422.  | 1.6 | 29        |
| 104 | Risk and Protective Factors Related to Early Adverse Life Events in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 63-69.   | 1.1 | 28        |
| 105 | Obesity is associated with a distinct brain-gut microbiome signature that connects <i>Prevotella</i> and <i>Bacteroides</i> to the brain's reward center. <i>Gut Microbes</i> , 2022, 14, 2051999.   | 4.3 | 28        |
| 106 | Risk Factors for Abdominal Pain-Related Disorders of Gut-Brain Interaction in Adults and Children: A Systematic Review. <i>Gastroenterology</i> , 2022, 163, 995-1023.e3.  | 0.6 | 28        |
| 107 | Predictors of Health-related Quality of Life in Irritable Bowel Syndrome Patients Compared With Healthy Individuals. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e142-e149.  | 1.1 | 27        |
| 108 | Is There a Difference Between Abdominal Pain and Discomfort in Moderate to Severe IBS Patients?. <i>American Journal of Gastroenterology</i> , 2002, 97, 3131-3138.  | 0.2 | 26        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Interactions of early adversity with stress-related gene polymorphisms impact regional brain structure in females. <i>Brain Structure and Function</i> , 2016, 221, 1667-1679.   | 1.2 | 26        |
| 110 | The Colonic Mucosal MicroRNAs, MicroRNA-219a-5p, and MicroRNA-338-3p Are Downregulated in Irritable Bowel Syndrome and Are Associated With Barrier Function and MAPK Signaling. <i>Gastroenterology</i> , 2021, 160, 2409-2422.e19.  | 0.6 | 26        |
| 111 | A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. <i>Gastroenterology</i> , 2000, 118, A846.   | 0.6 | 25        |
| 112 | The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1302-1312. | 1.9 | 25        |
| 113 | Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database. <i>American Journal of Gastroenterology</i> , 2014, 109, 234-248.  | 0.2 | 25        |
| 114 | Î²-opioid receptor, Î²-endorphin, and cannabinoid receptor 2 are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13688.   | 1.6 | 25        |
| 115 | Construct Validity of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2014, 66, 1725-1730.  | 1.5 | 24        |
| 116 | Sex-Related Differences in GI Disorders. <i>Handbook of Experimental Pharmacology</i> , 2017, 239, 177-192.  | 0.9 | 23        |
| 117 | Epigenetic Mechanisms in Irritable Bowel Syndrome. <i>Frontiers in Psychiatry</i> , 2020, 11, 805.   | 1.3 | 23        |
| 118 | Towards an integrative model of irritable bowel syndrome. <i>Progress in Brain Research</i> , 2000, 122, 413-423.  | 0.9 | 22        |
| 119 | Neuroendocrine and Neuroimmune Markers in IBS: Pathophysiological Role or Epiphenomenon?. <i>Gastroenterology</i> , 2006, 130, 596-600.  | 0.6 | 22        |
| 120 | Longitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1576-1584.  | 0.9 | 22        |
| 121 | Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. <i>American Journal of Gastroenterology</i> , 2010, 105, 722-730.  | 0.2 | 21        |
| 122 | Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13003.  | 1.6 | 21        |
| 123 | Negative Events During Adulthood Are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2245-2252.  | 2.4 | 21        |
| 124 | Computer versus physician identification of gastrointestinal alarm features. <i>International Journal of Medical Informatics</i> , 2015, 84, 1111-1117.  | 1.6 | 20        |
| 125 | Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e465-e483.   | 2.4 | 20        |
| 126 | Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. <i>American Journal of Gastroenterology</i> , 2021, 116, 1929-1937.   | 0.2 | 19        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Gene expression profiles in peripheral blood mononuclear cells correlate with salience network activity in chronic visceral pain: A pilot study. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13027.                                | 1.6 | 18        |
| 128 | Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 689-699. | 1.4 | 18        |
| 129 | Sigmoid colon mucosal gene expression supports alterations of neuronal signaling in irritable bowel syndrome with constipation. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, G140-G157.                              | 1.6 | 18        |
| 130 | The Role of Resilience in Irritable Bowel Syndrome, Other Chronic Gastrointestinal Conditions, and the General Population. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2541-2550.e1.  | 2.4 | 18        |
| 131 | Catecholaminergic Gene Polymorphisms Are Associated with GI Symptoms and Morphological Brain Changes in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2015, 10, e0135910.   | 1.1 | 18        |
| 132 | Contrasting Clinician and Insurer Perspectives to Managing Irritable Bowel Syndrome: Multilevel Modeling Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 748-757.  | 0.2 | 18        |
| 133 | Analysis of brain networks and fecal metabolites reveals brain-gut alterations in premenopausal females with irritable bowel syndrome. <i>Translational Psychiatry</i> , 2020, 10, 367.   | 2.4 | 17        |
| 134 | Postmenopausal women with irritable bowel syndrome (IBS) have more severe symptoms than premenopausal women with IBS. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13913.   | 1.6 | 17        |
| 135 | Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 813-821.e7.   | 1.5 | 17        |
| 136 | New Treatments for Irritable Bowel Syndrome in Women. <i>Women's Health</i> , 2008, 4, 605-622.   | 0.7 | 16        |
| 137 | Emerging Pharmacological Therapies for the Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 223-243.  | 1.0 | 16        |
| 138 | Functional Bowel Disorders. <i>Gastroenterology</i> , 2018, 155, 1-4.   | 0.6 | 16        |
| 139 | Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. <i>American Journal of Gastroenterology</i> , 2021, 116, 1601-1611.           | 0.2 | 15        |
| 140 | Admission factors can predict the need for ICU monitoring in gallstone pancreatitis. <i>American Surgeon</i> , 1996, 62, 815-9.   | 0.4 | 15        |
| 141 | Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1836-1844.   | 1.1 | 14        |
| 142 | Latest Insights on the Pathogenesis of Irritable Bowel Syndrome. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 505-522.  | 1.0 | 14        |
| 143 | Novel techniques to study visceral hypersensitivity in irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , 2008, 10, 369-378.   | 1.1 | 13        |
| 144 | A cross-cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015, 27, 490-500.                                  | 1.6 | 13        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Unconscious Bias in Peer Review. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 419-420.  | 2.4 | 13        |
| 146 | Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 291-305.   | 1.4 | 12        |
| 147 | Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984129. | 1.4 | 12        |
| 148 | Plasma Corticotropin-Releasing Factor Receptors and B7-2+ Extracellular Vesicles in Blood Correlate with Irritable Bowel Syndrome Disease Severity. <i>Cells</i> , 2019, 8, 101.   | 1.8 | 12        |
| 149 | Does mind-body medicine have a role in gastroenterology?. <i>Current Opinion in Gastroenterology</i> , 1997, 13, 1-4.  | 1.0 | 11        |
| 150 | Using the Rome IV Criteria to Help Manage the Complex IBS Patient. <i>American Journal of Gastroenterology</i> , 2018, 113, 453-456.   | 0.2 | 11        |
| 151 | Increasing Rates of Opioid Prescriptions for Gastrointestinal Diseases in the United States. <i>American Journal of Gastroenterology</i> , 2021, 116, 796-807.   | 0.2 | 11        |
| 152 | Brain-gut interactions: implications for newer therapy. <i>The European Journal of Surgery</i> , 2003, 164, 50-55.   | 1.0 | 9         |
| 153 | Benefits and Pitfalls of Change From Rome III to Rome IV Criteria for Irritable Bowel Syndrome and Fecal Incontinence. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 297-299.                              | 2.4 | 9         |
| 154 | Importance of trauma-related fear in patients with irritable bowel syndrome and early adverse life events. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13896.   | 1.6 | 9         |
| 155 | An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. <i>Gastroenterology and Hepatology</i> , 2010, 6, 1-12.   | 0.2 | 9         |
| 156 | Clostridial bacteremia: implications for the surgeon. <i>American Surgeon</i> , 1991, 57, 388-93.  | 0.4 | 9         |
| 157 | Early computed tomography is rarely necessary in gallstone pancreatitis. <i>American Surgeon</i> , 1997, 63, 904-7.  | 0.4 | 9         |
| 158 | Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response. <i>Psychoneuroendocrinology</i> , 2016, 73, 133-141.                       | 1.3 | 8         |
| 159 | A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 281-291.                   | 1.9 | 8         |
| 160 | Evidence for decreased activation of central fear circuits by expected aversive visceral stimuli in IBS patients. <i>Gastroenterology</i> , 2000, 118, A137.   | 0.6 | 7         |
| 161 | Irritable bowel syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2002, 5, 267-278.   | 0.3 | 7         |
| 162 | Irritable bowel syndrome: new and emerging therapies. <i>Current Opinion in Internal Medicine</i> , 2006, 5, 297-304.  | 1.5 | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Alosetron: An Effective Treatment for Diarrhea-Predominant Irritable Bowel Syndrome. <i>Women's Health</i> , 2007, 3, 15-27.   | 0.7 | 7         |
| 164 | 313 Effects of Rifaximin on Urgency, Bloating, and Abdominal Pain in Patients With IBS-D: A Randomized, Controlled, Repeat Treatment Study. <i>Gastroenterology</i> , 2015, 148, S-69.                             | 0.6 | 7         |
| 165 | The Gut Microbiome and Digestive Health – A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 215-217.   | 2.4 | 7         |
| 166 | Opioid Prescription Patterns Among US Gastroenterologists From 2013 to 2017. <i>Gastroenterology</i> , 2020, 158, 776-779.e2.  | 0.6 | 7         |
| 167 | Evolving pathophysiological model of functional gastrointestinal disorders: implications for treatment. <i>The European Journal of Surgery Supplement: = Acta Chirurgica Supplement</i> , 2002, , 3-9.             | 0.2 | 7         |
| 168 | Approaches to the Modulation of Abdominal Pain. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 1999, 13, 66A-70A.  | 1.8 | 6         |
| 169 | Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use. <i>Biological Research for Nursing</i> , 2021, 23, 171-179.                            | 1.0 | 6         |
| 170 | The Transition From Rome III to Rome IV Irritable Bowel Syndrome: What We Gain and Lose. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 508-510.  | 2.4 | 6         |
| 171 | How to Approach a Patient with Difficult-to-Treat IBS. <i>Gastroenterology</i> , 2021, 161, 1092-1098.e3.  | 0.6 | 6         |
| 172 | T1026 Measuring IBS Patient Reported Outcomes with a Single Item Numeric Rating Scale: Results from the PROOF Cohort. <i>Gastroenterology</i> , 2008, 134, A-467.  | 0.6 | 4         |
| 173 | Understanding the Multidimensional Nature of Illness Severity as Measured by Patient-Reported Outcome Measures in Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 918-919.    | 2.4 | 4         |
| 174 | Do Patients Understand the Bristol Stool Scale? Results of Cognitive De-Briefing of IBS Patients. <i>Gastroenterology</i> , 2011, 140, S-615.  | 0.6 | 4         |
| 175 | Mo1616 Resilience Is Decreased in Irritable Bowel Syndrome (IBS) and Associated With Poorer Quality of Life and Greater Symptom Severity. <i>Gastroenterology</i> , 2016, 150, S731.                               | 0.6 | 4         |
| 176 | 2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 394-399.e2. | 2.3 | 4         |
| 177 | 1090 - Epigenetic Changes in Blood Cells and Colonic Mucosa are Associated with Irritable Bowel Syndrome (IBS). <i>Gastroenterology</i> , 2018, 154, S-214.  | 0.6 | 4         |
| 178 | Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4140-4148.                         | 1.1 | 4         |
| 179 | An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-D. <i>Gastroenterology and Hepatology</i> , 2013, 9, 1-24.  | 0.2 | 4         |
| 180 | The visceral sensitivity index: A novel tool for measuring GI symptom-specific anxiety in inflammatory bowel disease. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14384.                                | 1.6 | 4         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | The role of gender and bowel habit predominance on visceral perception in IBS. <i>Gastroenterology</i> , 2001, 120, A755.  | 0.6 | 3         |
| 182 | Response to Drs Trivedi and Ward. <i>American Journal of Gastroenterology</i> , 2012, 107, 140-141.  | 0.2 | 3         |
| 183 | 2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e77-e86.                                       | 2.4 | 3         |
| 184 | Increased Sleep Disturbances in Irritable Bowel Syndrome (IBS) Patients is Associated with Greater Symptom Severity and Decreased Quality Of Life. <i>Gastroenterology</i> , 2017, 152, S716.  | 0.6 | 3         |
| 185 | Dysregulation of the Long-Noncoding RNA, Chrlos, in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S722.   | 0.6 | 3         |
| 186 | High Opioid Prescribing Profiles Among Gastroenterologists: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .   | 2.4 | 3         |
| 187 | Differences in rectal mechanoelastic properties according to predominant bowel habit in IBS patients. <i>Gastroenterology</i> , 2000, 118, A667.   | 0.6 | 2         |
| 188 | Ratings of sigmoid but not rectal distensions correlate with IBS symptom severity. <i>Gastroenterology</i> , 2000, 118, A445.  | 0.6 | 2         |
| 189 | Evidence for selective effect of the 5HT3 antagonist alosetron on amygdala and hippocampal activation in IBS patients. <i>Gastroenterology</i> , 2000, 118, A81.   | 0.6 | 2         |
| 190 | The effect of the 5-HT3 receptor antagonist alosetron on regional brain activation in IBS patients is not dependent on activation of nociceptive visceral afferents: A H2150 PET study. <i>Gastroenterology</i> , 2001, 120, A67.        | 0.6 | 2         |
| 191 | Clinical determinants of health-related quality of life in irritable bowel syndrome. <i>Gastroenterology</i> , 2003, 124, A398.  | 0.6 | 2         |
| 192 | Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>American Journal of Gastroenterology</i> , 2015, 110, S761. | 0.2 | 2         |
| 193 | 366 Guanylate Cyclase-C Expression Is Down-Regulated in Colonic Biopsies From Female Irritable Bowel Syndrome Patients With Constipation. <i>Gastroenterology</i> , 2016, 150, S81-S82.  | 0.6 | 2         |
| 194 | Do Proton Pump Inhibitors (PPIs) Predispose to the Development of SIBO in IBS versus Non-IBS Patients?. <i>American Journal of Gastroenterology</i> , 2009, 104, S103-S104.  | 0.2 | 2         |
| 195 | Guanylate Cyclase-C Receptor and Ligand Expression in Colonic Mucosa in Chronic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S540.   | 0.2 | 2         |
| 196 | Gender differences in autonomic activity in IBS. <i>Gastroenterology</i> , 2000, 118, A137.  | 0.6 | 1         |
| 197 | Mo1273 The Association of Early Adverse Life Events and Irritable Bowel Syndrome (IBS) Is Amplified by the Presence of Peritraumatic Fear. <i>Gastroenterology</i> , 2015, 148, S-656-S-657.   | 0.6 | 1         |
| 198 | Impact of Baseline Pain Severity on the Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. <i>American Journal of Gastroenterology</i> , 2016, 111, S254.  | 0.2 | 1         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | Colonic Mucosal Microbiome is Associated with Mucosal MicroRNA Expression in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S40-S41.   | 0.6 | 1         |
| 200 | Expression Profiling of Sigmoid Biopsies in Irritable Bowel Syndrome vs Healthy Controls. <i>Gastroenterology</i> , 2017, 152, S722.   | 0.6 | 1         |
| 201 | Is It Time to Abandon Gastric Emptying in Patients With Symptoms of Gastroparesis and Functional Dyspepsia?. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .   | 2.4 | 1         |
| 202 | Gender-Related Differences in Functional Bowel Disorders. , 2004, , 438-445.   |     | 1         |
| 203 | Is IBS a Predictor of SIBO as Identified by Hydrogen/Methane Breath Testing?. <i>American Journal of Gastroenterology</i> , 2009, 104, S110.   | 0.2 | 1         |
| 204 | Effects of Linaclotide on Abdominal and Bowel Symptoms Over the First Seven Days of Treatment in Patients with Irritable Bowel Syndrome with Constipation. <i>American Journal of Gastroenterology</i> , 2012, 107, S710-S711.                       | 0.2 | 1         |
| 205 | Effect of Eluxadoline on Abdominal and Bowel Symptoms Over Time in Phase 3 Clinical Trials in Patients With Irritable Bowel Syndrome With Diarrhea. <i>American Journal of Gastroenterology</i> , 2015, 110, S748.                                   | 0.2 | 1         |
| 206 | Negative Feedback of the Hypothalamic Pituitary Adrenal (HPA) Axis as Assessed by the Dexamethasone-Corticotropin Releasing Factor (CRF) Test in Irritable Bowel Syndrome (IBS). <i>American Journal of Gastroenterology</i> , 2015, 110, S755-S756. | 0.2 | 1         |
| 207 | Gender and Other Factors Associated with Endoscopy Volume Among U.S. Gastroenterology Fellows. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2911-2914.e4.   | 2.4 | 1         |
| 208 | Comment on "Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia" L. Chang et al., <i>PAIN</i> 84 (2000) 297-307. <i>Pain</i> , 2001, 91, 404-405.                                       | 2.0 | 0         |
| 209 | A Functional Promoter Variant in the Tryptophan Hydroxylase 1 Gene is Associated With a Bowel Habit Phenotype in Patients With Irritable Bowel Syndrome (IBS). <i>Gastroenterology</i> , 2011, 140, S-111.   | 0.6 | 0         |
| 210 | Factors Analysis of Bowel Symptoms in IBS: Guidance for Patient Reported Outcome (PRO) Development. <i>Gastroenterology</i> , 2011, 140, S-605-S-606.  | 0.6 | 0         |
| 211 | Treatment of bloating and distension - role of probiotics: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 581-583.  | 1.9 | 0         |
| 212 | Evaluation of the Patient Reported Outcomes Measurement Information System (PROMIS) in Celiac Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, S464.  | 0.2 | 0         |
| 213 | Tu1788 Corticotropin-Releasing Hormone Receptor 1 (CRH-R1) Polymorphisms are Associated With Irritable Bowel Syndrome (IBS) and Acoustic Startle Response (ASR). <i>Gastroenterology</i> , 2016, 150, S946-S947.                                     | 0.6 | 0         |
| 214 | Tu1794 Functional Pathways Associated With Differential Colonic Mucosal Expression of microRNA and mRNA in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 150, S949.  | 0.6 | 0         |
| 215 | Tu1799 Differences in Cortisol Responses to Hormone Challenge vs. Visceral Stressor in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 150, S950-S951.   | 0.6 | 0         |
| 216 | Tu1803 IBS-Associated SCN5A Mutation G615E Results in a NaV1.5 Channel With Normal Na+ Current Density but Loss of Mechanosensitivity. <i>Gastroenterology</i> , 2016, 150, S952.  | 0.6 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 217 | Tu1802 Colonic Immune Cells in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S951-S952.  | 0.6 | 0         |
| 218 | Trauma Severity and Lack of Confiding in Others Increases Risk of Having Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S711-S712.   | 0.6 | 0         |
| 219 | Resilience is Associated with Early Life Stress and HPA Axis Response in IBS. <i>Gastroenterology</i> , 2017, 152, S921.   | 0.6 | 0         |
| 220 | Sex-Dependent Alterations of Colonic Epithelial Permeability in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S723.   | 0.6 | 0         |
| 221 | Impact of Rifaximin on Health-Related Quality of Life in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S913.   | 0.6 | 0         |
| 222 | Predictors of Quality of Life in Irritable Bowel Syndrome Compared to Healthy Controls. <i>Gastroenterology</i> , 2017, 152, S714-S715.  | 0.6 | 0         |
| 223 | 487 Use of Central Neuromodulators by Gastroenterologists in the Treatment of IBS: A Pilot Survey. <i>American Journal of Gastroenterology</i> , 2019, 114, S282-S282.   | 0.2 | 0         |
| 224 | 489 Opioid and Neuromodulator Prescription Patterns Among U.S. Gastroenterologists. <i>American Journal of Gastroenterology</i> , 2019, 114, S283-S283.  | 0.2 | 0         |
| 225 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .   | 2.4 | 0         |
| 226 | 9-Year Evaluation of Temporal Trends in Alosetron Postmarketing Safety Under the Risk Management Program. <i>American Journal of Gastroenterology</i> , 2012, 107, S703-S704.                                  | 0.2 | 0         |
| 227 | MicroRNA targeting for the therapy of colitis-associated colon cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 571-571.   | 0.8 | 0         |
| 228 | The Effect of Sex and Irritable Bowel Syndrome (IBS) on the Integrated Hypothalamic-Pituitary-Adrenal (HPA) Axis Response to Hormone Challenge. <i>American Journal of Gastroenterology</i> , 2015, 110, S757. | 0.2 | 0         |
| 229 | The Long Non-Coding RNA AFDN-AS1 Is Expressed in Colonic Epithelial Cells. <i>American Journal of Gastroenterology</i> , 2018, 113, S262-S263.   | 0.2 | 0         |
| 230 | Pain Phenotypes in Chronic Pancreatitis: Beginning to Fine-tune Our Approach to Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, , .   | 2.4 | 0         |
| 231 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .   | 2.4 | 0         |